Remove 2014 Remove Labelling Remove Mayo Clinic
article thumbnail

ASH roundup: late breakers take the stage

pharmaphorum

Amgen’s Blincyto (blinatumomab) was the first bispecific T cell engager to be approved for marketing way back in 2014, but has been a slow burner product for Amgen, with sales rising slowly to $472 million last year in its main indication in B-cell acute lymphoblastic leukaemia (B-ALL). “We think we can do better,” he added.

article thumbnail

Hydroxyzine interactions to avoid

The Checkup by Singlecare

Your interest and inquisitions will be welcomed, and as a result, you will be safer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Melatonin side effects and how to avoid them

The Checkup by Singlecare

However, melatonin drug labels advise certain people to consult their healthcare provider before taking melatonin supplements. There have been numerous recalls of individual melatonin products for impurities, poor quality, or incorrect labeling. To date, there has been no industry-wide recall of melatonin supplements.

article thumbnail

Tamsulosin interactions to avoid

The Checkup by Singlecare

The FDA has not approved Tamsulosin for use in women and children, though at times, medical professionals may use the drug off-label in these populations for other indications. However, if it is almost time for your next dose, skip the missed dose. Do not double up. If you feel faint or fall, seek help immediately.